Summary
In most Canadian provinces, eligibility criteria for public reimbursement coverage
for tafamidis for treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM)
include tissue biopsy confirmation of amyloidosis. Carpal tunnel syndrome requiring
surgical release is common in ATTR-CM. We report our experience performing simultaneous
transverse carpal ligament and tenosynovium biopsy during CTR, with all patients positive
for amyloidosis, facilitating initiation of tafamidis.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.Can J Cardiol. Mar 2020; 36: 322-334https://doi.org/10.1016/j.cjca.2019.12.034
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.N Engl J Med. Sep 2018; 379: 1007-1016https://doi.org/10.1056/NEJMoa1805689
Technology CAfDaH. Canadian Drug Expert Reimbursement Recommendations - Tafamidis Meglumine. Common Drug Review. Ottawa, Ontario, Canada 2020. p. 1-8.
- The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.Circulation. Nov 06 2007; 116: 2216-2233https://doi.org/10.1161/CIRCULATIONAHA.107.186093
- Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.Am J Cardiol. May 15 2014; 113: 1723-1727https://doi.org/10.1016/j.amjcard.2014.02.030
Article Info
Publication History
Accepted:
June 9,
2022
Received in revised form:
May 22,
2022
Received:
February 11,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.
